Treprostinil for Pulmonary Arterial Hypertension
(ARTISAN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but you must be on a stable dose of certain medications like endothelin receptor antagonists or phosphodiesterase type 5 inhibitors, or be willing to start them along with the study drug.
How is the drug Treprostinil unique for treating pulmonary arterial hypertension?
Treprostinil is unique because it is available in multiple forms, including oral, inhaled, and injectable, which offers flexibility in administration. The oral form, Orenitram, is particularly novel as it provides the convenience of oral dosing, potentially improving patient compliance compared to other prostacyclin analogues that require more complex administration.12345
What data supports the effectiveness of the drug Treprostinil for treating pulmonary arterial hypertension?
Treprostinil, available in oral, inhaled, and injectable forms, has shown improvements in exercise capacity and survival in patients with pulmonary arterial hypertension. The oral form, Orenitram, offers the convenience of oral dosing and has been approved by the FDA after demonstrating improved exercise capacity in clinical trials.12456
Are You a Good Fit for This Trial?
This trial is for people with pulmonary arterial hypertension (PAH) who have a mean pulmonary artery pressure over 35 mmHg and are on stable PAH medication or willing to start it. They should be able to walk more than 165 meters, not have severe liver issues, and can't be using certain other medications or have conditions that affect heart imaging tests.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive early and rapid treprostinil therapy to reduce mean pulmonary artery pressure and improve right ventricular function
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Oral Treprostinil
- Parenteral Treprostinil
Oral Treprostinil is already approved in United States, Canada, European Union for the following indications:
- Pulmonary arterial hypertension (PAH)
- Pulmonary hypertension associated with interstitial lung disease
- Long-term treatment of pulmonary arterial hypertension in NYHA Class III and IV patients who did not respond adequately to conventional therapy
- Pulmonary arterial hypertension (PAH)
Find a Clinic Near You
Who Is Running the Clinical Trial?
United Therapeutics
Lead Sponsor
Dr. Martine Rothblatt
United Therapeutics
Chief Executive Officer since 1996
PhD in Medical Ethics from the Royal London College of Medicine and Dentistry, JD and MBA from UCLA
Dr. Michael Benkowitz
United Therapeutics
Chief Medical Officer since 2023
MD from Harvard Medical School
Lung Biotechnology PBC
Industry Sponsor